Common use
Viropil is a fixed-dose combination direct-acting antiviral (DAA) medication containing two powerful active ingredients — sofosbuvir and velpatasvir — used for the curative treatment of chronic hepatitis C (HCV) infection across all major viral genotypes. When you buy Viropil online, you receive a pangenotypic therapy that is clinically proven effective against all six major genotypes of the hepatitis C virus (genotypes 1 through 6), eliminating the need for costly and time-consuming genotype testing before initiating treatment in many clinical settings. As an Epclusa generic, Viropil offers the same revolutionary all-genotypes formula that has fundamentally transformed hepatitis C treatment worldwide, making a functional cure accessible to millions of patients. The sofosbuvir velpatasvir combination works through a powerful dual mechanism of action targeting two different essential viral proteins simultaneously. Sofosbuvir is a nucleotide analogue inhibitor that targets the NS5B RNA-dependent RNA polymerase — the enzyme the hepatitis C virus requires to copy its genetic material and replicate inside liver cells. By incorporating itself into the growing viral RNA chain and causing premature chain termination, sofosbuvir halts viral replication at its core. Velpatasvir is a next-generation NS5A inhibitor that targets the NS5A protein, a multifunctional protein essential for viral RNA replication, virion assembly, and secretion of new virus particles from infected hepatocytes. Together, this direct-acting antiviral combination delivers sustained virological response (SVR) rates — the medical definition of a hepatitis C cure — exceeding 95% across all genotypes in landmark clinical trials, including in patients who were previously considered difficult to treat, such as those with compensated cirrhosis. Viropil provides a simple, once-daily oral regimen that has completely eliminated the need for interferon injections and their notoriously debilitating side effects (severe flu-like symptoms, depression, anemia, and prolonged treatment courses of 24 to 48 weeks). The standard 12-week HCV treatment course with this pangenotypic antiviral is dramatically shorter, far better tolerated, and significantly more effective than the older interferon-based regimens.

Dosage and direction
Take one Viropil tablet once daily by mouth, with or without food, exactly as prescribed by your hepatologist, gastroenterologist, or infectious disease specialist. The standard course of HCV treatment with this direct-acting antiviral is 12 weeks for most patient populations, including those with chronic hepatitis C without cirrhosis and those with compensated cirrhosis (Child-Pugh class A). In patients with decompensated cirrhosis (Child-Pugh class B or C), your doctor will typically recommend extending the treatment to 12 weeks with the addition of weight-based ribavirin to the regimen to optimize cure rates in this more challenging population. Swallow the tablet whole with a full glass of water — do not crush, break, split, or chew it, as this may alter the carefully designed drug release characteristics and pharmacokinetics. It is important to take this sofosbuvir velpatasvir combination at approximately the same time every day to maintain consistent and optimal drug levels in the blood throughout the treatment course. Adherence to the prescribed schedule is not merely recommended — it is critical, as consistent dosing is directly linked to achieving a sustained virological response (SVR), which represents a complete and durable virological cure for chronic hepatitis C. Do not skip doses if at all possible, and do not stop treatment prematurely even if you start feeling better, your symptoms resolve, or interim blood tests show undetectable viral load before the treatment period ends. Completing the full prescribed 12-week course is essential to ensure complete viral eradication and prevent the emergence of drug-resistant viral variants that could complicate future treatment attempts.

Precautions
Before you buy Viropil, have a thorough discussion with your doctor about your complete medical history, current medications, and any co-existing conditions. This is particularly important if you have liver cirrhosis (especially decompensated cirrhosis with ascites, variceal bleeding, or hepatic encephalopathy), significant kidney disease or renal impairment (particularly if eGFR is below 30 mL/min), hepatitis B virus (HBV) co-infection, HIV co-infection, or a history of liver transplantation. Patients with hepatitis B co-infection require especially careful monitoring before, during, and after hepatitis C treatment, because successful HCV treatment can paradoxically trigger hepatitis B reactivation — a potentially serious and even fatal complication where the previously suppressed HBV begins replicating aggressively as the immune dynamics shift during and after HCV clearance. Your doctor should test all patients for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before starting this pangenotypic antiviral, and appropriate monitoring or concurrent HBV treatment should be arranged for co-infected patients. Regular monitoring of liver function tests (ALT, AST, bilirubin), kidney function (creatinine, eGFR), and HCV viral load is essential during treatment and for at least 12 weeks after completing therapy to confirm SVR (cure). If you are taking amiodarone for heart rhythm problems (atrial fibrillation, ventricular tachycardia), alert your doctor immediately and do not start Viropil without close cardiac monitoring, as the combination of amiodarone with sofosbuvir-containing products has been associated with cases of serious symptomatic bradycardia, including cases requiring pacemaker insertion and one fatal case. This cardiac risk may persist for weeks after amiodarone discontinuation due to amiodarone's extremely long half-life. Women of childbearing age must use effective contraception during treatment, particularly if ribavirin is added to the regimen, as ribavirin is a known teratogen (Category X) that causes severe birth defects and fetal death. Effective contraception must continue for at least 6 months after the last dose of ribavirin.

Contraindications
Do not take Viropil if you are allergic to sofosbuvir, velpatasvir, or any inactive ingredient in the tablet formulation. This Epclusa generic should not be co-administered with strong P-glycoprotein (P-gp) inducers or moderate-to-strong CYP enzyme inducers, including rifampin, rifabutin, rifapentine, St. John's wort (Hypericum perforatum), carbamazepine, phenobarbital, phenytoin, and oxcarbazepine. These drugs significantly reduce the plasma concentrations of both sofosbuvir and velpatasvir through enzyme induction, potentially dropping drug levels below the threshold needed for viral suppression and seriously compromising treatment efficacy, leading to virological failure and possible emergence of resistance. Patients currently taking amiodarone should not initiate this hepatitis C medication without close inpatient cardiac monitoring for at least 48 hours, followed by outpatient monitoring for at least 2 weeks, due to the risk of life-threatening bradycardia. If ribavirin is included in the treatment plan, all contraindications for ribavirin must also be strictly observed, including absolute contraindication in pregnancy and in male partners of pregnant women, severe pre-existing anemia (hemoglobin below 10 g/dL), hemoglobinopathies, severe cardiac disease, and severe hepatic decompensation beyond Child-Pugh class B.

Possible side effect
This direct-acting antiviral combination is generally very well tolerated, with a favorable safety profile that is dramatically superior to older interferon-based hepatitis C treatments. Common side effects reported during the 12-week HCV treatment course are typically mild and manageable, and may include headache (the most frequently reported side effect), fatigue, nausea, mild diarrhea, nasopharyngitis (common cold-like symptoms), and insomnia or irritability. Most of these side effects are transient and do not require treatment discontinuation. When Viropil is used in combination with ribavirin (as recommended for decompensated cirrhosis patients), the side effect profile broadens to include ribavirin-related adverse effects such as hemolytic anemia (which may require ribavirin dose reduction or erythropoiesis-stimulating agents), skin rash, decreased appetite, cough, and shortness of breath. Regular blood count monitoring is essential when ribavirin is part of the regimen. Serious but rare adverse effects that require immediate medical attention include symptomatic bradycardia (slow heart rate with dizziness, lightheadedness, fainting, or near-syncope — particularly in patients taking or recently taking amiodarone), hepatitis B reactivation in co-infected patients (presenting as fatigue, jaundice, dark urine, clay-colored stools, and elevated liver enzymes), and severe allergic reactions (rash, angioedema, difficulty breathing). Contact your healthcare provider promptly if you experience persistent or worsening fatigue, yellowing of the skin or whites of the eyes (jaundice), dark brown urine, persistent nausea or vomiting, right upper abdominal pain, or any signs suggestive of an allergic reaction.

Drug interaction
Inform your doctor about all medications, supplements, vitamins, and herbal products you take before starting this sofosbuvir velpatasvir combination, as Viropil has several clinically important drug interactions that can affect treatment efficacy or safety. Acid-reducing agents represent one of the most important interaction categories: proton pump inhibitors (PPIs such as omeprazole, esomeprazole, lansoprazole, pantoprazole) can significantly reduce velpatasvir absorption by raising gastric pH. If a PPI is medically necessary, the maximum recommended dose is omeprazole 20 mg (or equivalent), and it must be taken at the same time as Viropil under fasting conditions. H2-receptor antagonists (famotidine, ranitidine) should be taken simultaneously with or 12 hours before Viropil at doses not exceeding famotidine 40 mg equivalent. Antacids should be separated by at least 4 hours from Viropil administration. Anticonvulsants (phenytoin, carbamazepine, phenobarbital, oxcarbazepine), antimycobacterial agents (rifampin, rifabutin, rifapentine), and St. John's wort are strictly contraindicated due to their potent enzyme-inducing effects that dramatically reduce antiviral drug levels and can cause virological failure. Certain HIV antiretroviral medications require careful evaluation: regimens containing tenofovir disoproxil fumarate (TDF) may require enhanced renal monitoring due to increased tenofovir exposure, while efavirenz-based regimens are generally not recommended with velpatasvir due to reduced velpatasvir levels. Tipranavir/ritonavir is contraindicated. Statins metabolized by CYP enzymes (particularly rosuvastatin and atorvastatin) may need dose modification or temporary discontinuation during this all-genotypes HCV treatment, as velpatasvir can increase statin levels and the risk of myopathy. Amiodarone poses a uniquely serious interaction risk due to the potential for life-threatening symptomatic bradycardia, as discussed in the precautions and contraindications sections.

Missed dose
If you miss a dose of Viropil, take it as soon as you remember on the same day, regardless of whether it is close to a meal or not. If it is already close to the time for your next scheduled dose (within 12 hours), skip the missed one and resume your regular once-daily schedule the following day. Do not take two tablets at once or within a short time interval to make up for a missed dose, as this does not improve efficacy and may increase the risk of side effects. Consistent daily dosing is crucial for the success of this all-genotypes HCV treatment, as maintaining adequate and uninterrupted drug levels is directly linked to sustained virological response rates. If you miss multiple consecutive doses or have gaps of two or more days in therapy, contact your healthcare provider for guidance, as significant interruptions may reduce the effectiveness of viral clearance, potentially allow viral rebound, and in rare cases may contribute to the selection of drug-resistant viral variants that could compromise the current or future treatment courses.

Overdose
Seek emergency medical help immediately if an overdose of this Epclusa generic is suspected. Although limited data are available on Viropil overdose in humans, symptoms may include exaggerated and more severe versions of common side effects such as severe fatigue, intense nausea, persistent headache, gastrointestinal disturbance, and potentially hepatotoxicity at very high doses. There is no specific antidote for sofosbuvir or velpatasvir overdose. General supportive measures should be employed, including close monitoring of vital signs, cardiac rhythm monitoring, observation of clinical status, and assessment of liver and kidney function. Hemodialysis is not expected to effectively remove sofosbuvir's active metabolite (GS-461203) or velpatasvir from the systemic circulation due to their high protein binding (velpatasvir is approximately 99.5% protein-bound). Sofosbuvir itself is efficiently extracted by hemodialysis (extraction ratio of approximately 53%), but the clinical utility of dialysis in overdose is uncertain. Contact your local poison control center or emergency medical services for guidance on management of suspected overdose.

Storage
Store Viropil at room temperature below 86°F (30°C) in a dry place, well protected from moisture, humidity, and direct sunlight that could degrade the active pharmaceutical ingredients. Keep the container or blister pack tightly closed and store this hepatitis C medication out of reach of children and pets at all times. Do not remove tablets from blister packaging until ready to take them, as this exposes the tablets to environmental moisture. Do not use Viropil past its printed expiration date, as the potency and stability of the direct-acting antiviral compounds cannot be guaranteed after expiration. Properly dispose of any unused or expired tablets according to local pharmacy disposal guidelines or through a medication take-back program — do not flush medications down the toilet or discard in household trash unless specifically directed to do so.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.